Key result
Levosimendan infusion significantly increased peak VO2 (from 9.8 to 11.0 mL/kg/min, P<0.005) and reduced VE/VCO2 slope and BNP in patients with advanced chronic heart failure.
Why the study?
Does levosimendan improve cardiopulmonary exercise test parameters in patients with advanced chronic heart failure?
RCT (n=42)
Double-blind
randomly assigned
Does levosimendan improve cardiopulmonary exercise test parameters in patients with advanced chronic heart failure?
Absolute Event Rate: 11% vs 10%
p-value: p=<0.005
Levosimendan infusion significantly improves exercise performance parameters (peak VO2 and VE/VCO2 slope) and reduces BNP in patients with advanced chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Supports levosimendan to improve exercise capacity in advanced HF; extends RCT evidence on CPET and BNP benefits.
Mushtaq et al. (2015) conducted an RCT in advanced chronic heart failure (n=42). levosimendan vs. placebo was evaluated on Peak VO2 (mL/kg/min) (p=<0.005). Levosimendan infusion significantly increased peak VO2 (from 9.8 to 11.0 mL/kg/min, P<0.005) and reduced VE/VCO2 slope and BNP in patients with advanced chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: